Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, Chief Medical Officer | August 03, 2019 | August 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date August 03, 2019 · Filed August 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,584 |
Reported balance
After 2019-08-03 transaction · row 1
1 source rowRow 1 · 2019-08-03 · Sale · Disposed 1,328 · Balance 38,584 F1: The reported disposition of 1,328 shares represents the shares that were sold by the reporting person to cover minimum statutory obligations due upon vesting of 3,750 restricted stock award shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 1,328 shares represents the shares that were sold by the reporting person to cover minimum statutory obligations due upon vesting of 3,750 restricted stock award shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2019 Filed Aug 6, 2019 00:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,328 | $16.70 | $22,177.60 |
DisclosureSEC source: 0001179110-19-009165 · edgar.xml · nonDerivative · entry 1 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,584 F1 · shares: The reported disposition of 1,328 shares represents the shares that were sold by the reporting person to cover minimum statutory obligations due upon vesting of 3,750 restricted stock award shares. Read SEC document |
| June 01, 2019 Filed Jun 3, 2019 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 2,043 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007033 · edgar.xml · derivative · entry 3 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,084 Underlying: Common Stock · 2,043 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| June 01, 2019 Filed Jun 3, 2019 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 706 | $14.75 | $10,413.50 |
DisclosureSEC source: 0001179110-19-007033 · edgar.xml · nonDerivative · entry 2 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,912 F1 · shares: The reported disposition of 706 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| June 01, 2019 Filed Jun 3, 2019 21:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 2,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007033 · edgar.xml · nonDerivative · entry 1 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 3,884 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002465 · edgar.xml · derivative · entry 3 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,767 Underlying: Common Stock · 3,884 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,343 | $16.81 | $22,575.83 |
DisclosureSEC source: 0001179110-19-002465 · edgar.xml · nonDerivative · entry 2 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,575 F1 · shares: The reported disposition of 1,343 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 3,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002465 · edgar.xml · nonDerivative · entry 1 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 22:36 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,790 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002007 · edgar.xml · derivative · entry 3 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,370 Underlying: Common Stock · 6,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 22:36 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,322 | $16.54 | $38,405.88 |
DisclosureSEC source: 0001179110-19-002007 · edgar.xml · nonDerivative · entry 2 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,067 F1 · shares: The reported disposition of 2,322 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 22:36 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002007 · edgar.xml · nonDerivative · entry 1 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 37,538 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001934 · edgar.xml · derivative · entry 2 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,538 Underlying: Common Stock · 37,538 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 71,602 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001179110-19-001934 · edgar.xml · derivative · entry 1 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,602 Underlying: Common Stock · 71,602 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 03, 2019 Filed Feb 5, 2019 21:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,503 | $16.12 | $40,348.36 |
DisclosureSEC source: 0001179110-19-001321 · edgar.xml · nonDerivative · entry 1 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,599 F1 · shares: The reported disposition of 2,503 shares represents the shares that were withheld by the issuer as payment for minimum statutory obligations due upon vesting of 6,165 restricted stock award shares. Read SEC document |
| February 03, 2019 Filed Feb 21, 2019 01:10 UTC Amendment | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 2,536 | $16.41 | $41,615.76 |
DisclosureSEC source: 0001179110-19-002193 · edgar.xml · nonDerivative · entry 1 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,566 F1 · kind: On February 5, 2019, the reporting person filed a Form 4 reporting the disposition of 2,503 shares at a price of $16.12 per share representing the shares that were sold to pay minimum statutory tax withholding obligations due upon vesting of 6,165 restricted stock award shares. This report is being filed to correct the transaction code, the total number of shares sold, the price per share received upon disposition and the aggregate beneficial ownership of the reporting person as of February 3, 2019, which will be updated in Forms 4 filed after the date of this amendment. F1 · shares: On February 5, 2019, the reporting person filed a Form 4 reporting the disposition of 2,503 shares at a price of $16.12 per share representing the shares that were sold to pay minimum statutory tax withholding obligations due upon vesting of 6,165 restricted stock award shares. This report is being filed to correct the transaction code, the total number of shares sold, the price per share received upon disposition and the aggregate beneficial ownership of the reporting person as of February 3, 2019, which will be updated in Forms 4 filed after the date of this amendment. F1 · price: On February 5, 2019, the reporting person filed a Form 4 reporting the disposition of 2,503 shares at a price of $16.12 per share representing the shares that were sold to pay minimum statutory tax withholding obligations due upon vesting of 6,165 restricted stock award shares. This report is being filed to correct the transaction code, the total number of shares sold, the price per share received upon disposition and the aggregate beneficial ownership of the reporting person as of February 3, 2019, which will be updated in Forms 4 filed after the date of this amendment. F1 · balance_after: On February 5, 2019, the reporting person filed a Form 4 reporting the disposition of 2,503 shares at a price of $16.12 per share representing the shares that were sold to pay minimum statutory tax withholding obligations due upon vesting of 6,165 restricted stock award shares. This report is being filed to correct the transaction code, the total number of shares sold, the price per share received upon disposition and the aggregate beneficial ownership of the reporting person as of February 3, 2019, which will be updated in Forms 4 filed after the date of this amendment. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 22:58 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,305 | $17.08 | $22,289.40 |
DisclosureSEC source: 0001179110-18-010332 · edgar.xml · nonDerivative · entry 1 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,102 F1 · shares: The reported disposition of 1,305 shares represents the shares that were withheld by the issuer as payment for minimum statutory obligations due upon vesting of 3,750 restricted stock award shares. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 2,043 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008049 · edgar.xml · derivative · entry 3 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,127 Underlying: Common Stock · 2,043 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 712 | $18.59 | $13,236.08 |
DisclosureSEC source: 0001179110-18-008049 · edgar.xml · nonDerivative · entry 2 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,407 F1 · shares: The reported disposition of 712 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 2,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008049 · edgar.xml · nonDerivative · entry 1 Chondros Dimitrios · CIK 0001739693 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.